Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
125 hedge funds and large institutions have $1.02B invested in Aimmune Therapeutics in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 49 increasing their positions, 28 reducing their positions, and 21 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 28
38% more call options, than puts
Call options by funds: $5.91M | Put options by funds: $4.29M
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
0% more funds holding
Funds holding: 125 → 125 (0)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less capital invested
Capital invested by funds: $1.07B → $1.02B (-$45.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.7M |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$5.38M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
-$17.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.94M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.65M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$5.99M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$4.08M |
AIMT Hedge Fund Activity: Q2 2019 in Review
125 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2019, worth a combined $1.02B — down 4.3% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AIMT positions and 21 closed out — a net gain of 2 holders — while 49 added to existing stakes and 28 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $16.7M. The largest seller was Southpoint Capital Advisors, exiting entirely with an estimated $17.9M sold.
- 125 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $1.02B of Aimmune Therapeutics stock for Q2 2019, down 4.3% quarter-over-quarter.
- 23 funds opened new Aimmune Therapeutics positions in Q2 2019 and 21 closed out, a net change of +2 holders.
- The largest Aimmune Therapeutics buyer in Q2 2019 was Eventide Asset Management, an estimated $16.7M added.
- The largest Aimmune Therapeutics seller in Q2 2019 was Southpoint Capital Advisors, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2019.